AbbVie Announces VRAYLAR Receives Reimbursement Recommendation From Canada's Drug Agency For Treatment Of Schizophrenia In Adults Following Successful Negotiations And LOI
Portfolio Pulse from Benzinga Newsdesk
AbbVie's VRAYLAR, an atypical antipsychotic medication, has received a reimbursement recommendation from Canada's drug agency for treating schizophrenia in adults. This follows successful negotiations and a letter of intent, leading to its listing in Québec and federal plans.
September 04, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's VRAYLAR has been recommended for reimbursement by Canada's drug agency for schizophrenia treatment, following successful negotiations. This could enhance VRAYLAR's market presence in Canada.
The reimbursement recommendation and listing in Canadian plans can increase VRAYLAR's sales and market penetration in Canada, positively impacting AbbVie's revenue from this product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90